Fibroblast Growth Factor (FGF) Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
AP 24534 inhibits FGF-6 signaling by directly targeting and inhibiting the activity of multiple tyrosine kinases, including BCR-ABL and FGFRs, which are crucial for FGF-6 mediated cellular processes. This inhibition disrupts the phosphorylation cascade essential for FGF-6 signal transduction, leading to impaired cellular proliferation and differentiation associated with FGF-6 pathways. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is a potent and selective FGFR inhibitor that directly targets the tyrosine kinase domain, preventing autophosphorylation and downstream signaling. | ||||||
SU 5402 | 215543-92-3 | sc-204308 sc-204308A | 1 mg 5 mg | $63.00 $98.00 | 36 | |
SU5402 is a small molecule inhibitor of FGFR tyrosine kinase activity. It interferes with the ATP-binding site of FGFR, preventing autophosphorylation and downstream signaling. | ||||||
AZD4547 | 1035270-39-3 | sc-364421 sc-364421A | 5 mg 10 mg | $198.00 $309.00 | 6 | |
AZD4547 is a selective FGFR inhibitor that hinders FGFR autophosphorylation and downstream signaling. By targeting the kinase domain, AZD4547 directly inhibits FGFR, disrupting FGF-mediated cellular processes including proliferation and angiogenesis. | ||||||
BGJ398 | 872511-34-7 | sc-364430 sc-364430A sc-364430B sc-364430C | 5 mg 10 mg 50 mg 100 mg | $216.00 $252.00 $594.00 $1009.00 | 4 | |
BGJ398 is an active inhibitor of FGFR tyrosine kinases. By binding to the ATP-binding pocket of FGFR, it prevents autophosphorylation and downstream signaling. BGJ398 directly inhibits FGFR, disrupting FGF-mediated pathways and cellular responses related to cell proliferation and angiogenesis. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Lenvatinib acts as a potent inhibitor of FGF-6 through its multi-targeted action on vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and fibroblast growth factor receptors (FGFRs), including those involved in FGF-6 signaling. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
JNJ-42756493 is a potent and selective FGFR inhibitor that interferes with the tyrosine kinase domain, preventing autophosphorylation and downstream signaling. By directly inhibiting FGFR, JNJ-42756493 disrupts FGF-mediated pathways, influencing cellular processes such as proliferation and angiogenesis. | ||||||
JNJ-26481585 | 875320-29-9 | sc-364515 sc-364515A | 5 mg 50 mg | $321.00 $1224.00 | ||
JNJ-26481585 is an active inhibitor of FGFR tyrosine kinase activity. By binding to the ATP-binding site, it inhibits autophosphorylation and downstream signaling. JNJ-26481585 directly targets FGFR, disrupting FGF-mediated pathways and cellular responses related to cell growth and angiogenesis. | ||||||